Article on BioWorld by Trista Morrison
Biotech firms have long borrowed ideas from the high tech world. The venture-backed start-up business model on which the entire biotech industry is based came from high tech, and it has served both industries well despite their very different timelines and cost structures. Even so, current capital constraints have put “unprecedented strain” on biotech business models, according to Ernst & Young’s Lead Analyst Gautam Jaggi, requiring a rethink of everything from company founding to drug development to healthcare delivery.
…
Similarly, entrepreneurs with expertise in artificial intelligence founded BioVista Inc. to create a drug profiling platform that would be able to identify new uses for existing compounds. …
Read More…